Management Strategies for Mixed GH and Prolactin-Secreting Macroadenomas Following Surgical Failure: A Case Report

Yosra Hasni, Sawsen Nouira, Hamza EL Fekih, Maissa Thabet, Wiem Ssafi, Nawres Thabet, Imen Halloul, Ghada Saad and Amel Maaroufi
Additional contact information
Yosra Hasni: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Sawsen Nouira: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Hamza EL Fekih: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Maissa Thabet: Department of Interne Medicine, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Wiem Ssafi: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Nawres Thabet: Ear Nose and Throat Department, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Imen Halloul: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Ghada Saad: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
Amel Maaroufi: Department of Endocrinology and Diabetology, Farhat Hached University Hospital, Sousse; Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia

Journal of Innovations in Medical Research, 2024, vol. 3, issue 4, 7-12

Abstract: Introduction: Acromegaly is a rare endocrine disorder characterized by excessive growth hormone (GH) production, leading to various complications. The primary treatment goal is to reduce GH and IGF-I levels, with options including surgical resection, medical therapy (e.g., somatostatin receptor ligands (SRLs), dopamine agonists, and pegvisomant), and radiotherapy. The rate of biochemical control reported varies widely across different studies. Case Presentation: A 28-year-old woman with clinically evident acromegaly, characterized by physical changes, was referred due to symptoms including snoring, dental spacing, profuse sweating, joint aches, headaches, visual blurring, and amenorrhea. She had no hypertension, galactorrhea, or diabetes mellitus. Clinical examination revealed a clear acromegalic phenotype and a thyroid goiter. Initial tests showed elevated IGF-1(687 µg/L), high prolactin (165 ng/ml), normal glucose tolerance, and normal lipid profile. MRI identified a large hyperintense mass with supra- and latero-sellar extension. Campimetry revealed a bitemporal hemianopsia in both the right and left eyes. The patient underwent transsphenoidal surgery, with histology confirming a GH/PRL adenoma. At 3 months, residual tumor was still present, and IGF-1 levels were elevated. The treatment with cabergoline and lanreotide for four years did not achieve biological or tumor control of the tumor residue, despite dosage increases. However, switching to pasireotide led to the normalization of IGF-1 levels after four months, although this was accompanied by an increase in fasting blood glucose levels. Conclusion: In summary, this case highlights the effective use of pasireotide, in combination with the dopamine agonist cabergoline, for managing acromegaly in a patient with residual disease. It underscores the importance of personalized treatment plans and the necessity for ongoing monitoring and therapy adjustments to achieve the best possible outcomes.

Keywords: acromegaly; somatostatin receptor ligands; resistance; pasireotide (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.paradigmpress.org/jimr/article/view/1382/1216 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bdz:joimer:v:3:y:2024:i:4:p:7-12

DOI: 10.56397/JIMR/2024.12.02

Access Statistics for this article

More articles in Journal of Innovations in Medical Research from Paradigm Academic Press
Bibliographic data for series maintained by Editorial Office ().